Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.
J Allergy Clin Immunol. 2022 Jan;149(1):432-439.e4. doi: 10.1016/j.jaci.2021.05.014. Epub 2021 May 25.
A novel autoinflammatory syndrome was recently described in male patients who harbored somatic mutations in the X-chromosomal UBA1 gene. These patients were characterized by adult-onset, treatment-refractory inflammation with fever, cytopenia, dysplastic bone marrow, vacuoles in myeloid and erythroid progenitor cells, cutaneous and pulmonary inflammation, chondritis, and vasculitis, which is abbreviated as VEXAS.
This study aimed to (retrospectively) diagnose VEXAS in patients who had previously been registered as having unclassified autoinflammation. We furthermore aimed to describe clinical experiences with this multifaceted, complex disease.
A systematic reanalysis of whole-exome sequencing data from a cohort of undiagnosed patients with autoinflammation from academic hospitals in The Netherlands was performed. When no sequencing data were available, targeted Sanger sequencing was applied in cases with high clinical suspicion of VEXAS.
A total of 12 male patients who carried mutations in UBA1 were identified. These patients presented with adult-onset (mean age 67 years, range 47-79 years) autoinflammation with systemic symptoms, elevated inflammatory parameters, and multiorgan involvement, most typically involving the skin and bone marrow. Novel features of VEXAS included interstitial nephritis, cardiac involvement, stroke, and intestinal perforation related to treatment with tocilizumab. Although many types of treatment were initiated, most patients became treatment-refractory, with a high mortality rate of 50%.
VEXAS should be considered in the differential diagnosis of males with adult-onset autoinflammation characterized by systemic symptoms and multiorgan involvement. Early diagnosis can prevent unnecessary diagnostic procedures and provide better prognostic information and more suitable treatment options, including stem cell transplantation.
最近在 X 染色体 UBA1 基因上存在体细胞突变的男性患者中描述了一种新的自身炎症综合征。这些患者的特征为成年发病、治疗抵抗的炎症,伴有发热、细胞减少、骨髓发育不良、髓系和红系祖细胞有空泡、皮肤和肺部炎症、软骨炎和血管炎,简称 VEXAS。
本研究旨在(回顾性)诊断先前被登记为未分类自身炎症的患者中的 VEXAS。我们还旨在描述这种多方面、复杂疾病的临床经验。
对来自荷兰学术医院的未确诊自身炎症患者队列的全外显子组测序数据进行了系统的重新分析。当没有测序数据时,对临床高度怀疑 VEXAS 的病例应用靶向 Sanger 测序。
共鉴定出 12 名携带 UBA1 突变的男性患者。这些患者表现为成年发病(平均年龄 67 岁,范围 47-79 岁)的自身炎症,伴有全身症状、炎症参数升高和多器官受累,最常见的是皮肤和骨髓受累。VEXAS 的新特征包括间质性肾炎、心脏受累、中风和与托珠单抗治疗相关的肠穿孔。尽管开始了多种类型的治疗,但大多数患者仍对治疗产生抵抗,死亡率高达 50%。
对于以全身症状和多器官受累为特征的成年发病自身炎症的男性患者,应考虑进行 VEXAS 的鉴别诊断。早期诊断可以防止不必要的诊断程序,并提供更好的预后信息和更合适的治疗选择,包括干细胞移植。